Special Issue

Diagnosis of Adverse Reactions to Drugs

Message from the Guest Editors

Adverse drug reactions (ADRs) affect all body organ systems and vary widely in severity. According to the World Health Organization, ADRs are one of the most common causes of morbidity and mortality; thus, they represent a financial burden for health care providers and the pharmaceutical industry. Non-serious ADRs are often resolved rapidly after removal of the casual drug; sometimes, after dose reduction, re-administration of the suspicious drug with the subsequent reappearance of the ADR is the gold standard diagnostic. However, in serious ADRs, which can lead to significant injury to organs/tissues which can be fatal, re-exposure is contraindicated for ethical reasons because its effects can be deadly. Most serious ADRs appear in the postcommercialization period. Therefore, a series of stakeholders would benefit from the development of solid diagnostics for early detection, and improve the forecast of serious ADRs.

Guest Editors

Dr. Elena Ramírez

Clinical Pharmacology, La Paz University Hospital—IdiPAZ, School of Medicine, Universidad Autónoma de Madrid, 28026 Madrid, Spain

Dr. Miguel González-Muñoz

Unit of Immunology, La Paz University Hospital, 28046 Madrid, Spain

Deadline for manuscript submissions

closed (31 December 2023)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/102289

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

